163 related articles for article (PubMed ID: 26915625)
1. Chronic Myeloid Leukemia With Rare Variant b2a3 (e13a3) BCR-ABL1 Fusion.
Ha J; Cheong JW; Shin S; Lee ST; Choi JR
Ann Lab Med; 2016 May; 36(3):287-9. PubMed ID: 26915625
[No Abstract] [Full Text] [Related]
2. [Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
Togitani K; Asagiri T; Kamioka M; Kojima K
Rinsho Ketsueki; 2021; 62(3):180-185. PubMed ID: 33828011
[TBL] [Abstract][Full Text] [Related]
3. Concurrence of e1a2 and e19a2 BCR-ABL1 Fusion Transcripts in a Typical Case of Chronic Myeloid Leukemia.
Lee J; Kim DS; Lee HS; Choi SI; Cho YG
Ann Lab Med; 2017 Jan; 37(1):74-76. PubMed ID: 27834071
[No Abstract] [Full Text] [Related]
4. Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Snyder DS; McMahon R; Cohen SR; Slovak ML
Am J Hematol; 2004 Feb; 75(2):92-5. PubMed ID: 14755375
[TBL] [Abstract][Full Text] [Related]
5. A novel, variant BCR-ABL1 transcript not detected by standard real-time quantitative PCR in a patient with chronic myeloid leukaemia.
McCarron SL; Haslam K; Kelly J; Duggan C; Langabeer SE
Int J Lab Hematol; 2012 Feb; 34(1):e1-2. PubMed ID: 21692997
[No Abstract] [Full Text] [Related]
6. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
Duan MH; Li H; Cai H
Leuk Res; 2017 Aug; 59():8-11. PubMed ID: 28527402
[TBL] [Abstract][Full Text] [Related]
7. Complete cytogenetic response to Nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: A case report.
Liu B; Zhang W; Ma H
Mol Med Rep; 2016 Mar; 13(3):2635-8. PubMed ID: 26847385
[TBL] [Abstract][Full Text] [Related]
8. Characterization of a novel variant BCR-ABL1 fusion transcript in a patient with chronic myeloid leukemia: Implications for molecular monitoring.
Crampe M; Haslam K; Kelly J; Conneally E; Langabeer SE
Hematol Oncol Stem Cell Ther; 2017 Jun; 10(2):85-88. PubMed ID: 27013275
[TBL] [Abstract][Full Text] [Related]
9. A novel aberrant form of e13a2 BCR-ABL1 transcript in chronic myelogenous leukemia undetectable with the standardized real-time quantitative polymerase chain reaction from the Europe Against Cancer Program.
Matsushita H; Yamamoto M; Tsuboi K; Masukawa A; Arakawa S; Asai S; Ogawa Y; Ando K; Miyachi H
Clin Chem Lab Med; 2009; 47(7):885-7. PubMed ID: 19575551
[No Abstract] [Full Text] [Related]
10. Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.
Liu LG; Tanaka H; Ito K; Kyo T; Ito T; Kimura A
Am J Hematol; 2003 Dec; 74(4):268-72. PubMed ID: 14635208
[TBL] [Abstract][Full Text] [Related]
11. Standardized Molecular Monitoring for Variant BCR-ABL1 Transcripts in Chronic Myeloid Leukemia.
Langabeer SE
Arch Pathol Lab Med; 2015 Aug; 139(8):969. PubMed ID: 26230589
[No Abstract] [Full Text] [Related]
12. Comparison of BCR/ABL1 mRNA levels by quantitative real-time PCR in peripheral blood and bone marrow specimens of patients with chronic myelogenous leukemia.
Thomas JS; Jagasia M; Vnencak-Jones CL
Leuk Lymphoma; 2017 Sep; 58(9):1-4. PubMed ID: 28278720
[No Abstract] [Full Text] [Related]
13. Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients.
Ballestrero A; Cirmena G; Dominietto A; Garuti A; Rocco I; Cea M; Moran E; Nencioni A; Miglino M; Raiola AM; Bacigalupo A; Patrone F
Int J Lab Hematol; 2010 Aug; 32(4):387-91. PubMed ID: 19968720
[TBL] [Abstract][Full Text] [Related]
14. Unusual location of BCR-ABL1 fusion sequences in a chronic myeloid leukemia patient.
Zámečníkova A; Al Bahar S; Pandita R
Hematology; 2012 Nov; 17(6):321-4. PubMed ID: 22989955
[TBL] [Abstract][Full Text] [Related]
15. Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients.
Al-Achkar W; Moassass F; Youssef N; Wafa A
J BUON; 2016; 21(2):444-9. PubMed ID: 27273956
[TBL] [Abstract][Full Text] [Related]
16. A rare, in-frame BCR-ABL fusion (e13a3) in a patient with an aggressive chronic myeloid leukaemia.
Otazú IB; Belén Rivero M; Olício R; Pinto A; Zalcberg I; Seuánez HN
Acta Haematol; 2002; 108(3):150-3. PubMed ID: 12373087
[TBL] [Abstract][Full Text] [Related]
17. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
Yaghmaie M; Ghaffari SH; Ghavamzadeh A; Alimoghaddam K; Jahani M; Mousavi SA; Irvani M; Bahar B; Bibordi I
Arch Iran Med; 2008 May; 11(3):247-51. PubMed ID: 18426313
[TBL] [Abstract][Full Text] [Related]
18. [Atypical BCR-ABL transcripts in patients with chronic myeloid leukemia--the scheme for the diagnosis and monitoring of minimal residual disease].
Link-Lenczowska D; Sacha T; Zawada M; Czekalska S; Florek I; Skotnicki AB
Przegl Lek; 2014; 71(5):258-62. PubMed ID: 25248240
[TBL] [Abstract][Full Text] [Related]
19. The first report of chronic myelogenous leukemia with e19a2 micro-BCR/ABL1 presenting with massive myelofibrosis.
Kim HY; Park S; Kim SH; Kim HJ
Blood Cells Mol Dis; 2017 Jun; 65():68-70. PubMed ID: 28571780
[No Abstract] [Full Text] [Related]
20. Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.
Xu D; Claudiani S; Naresh K; Mucklow S; Neelakantan P; Yebra E; Apperley JF; Khorashad J; Milojkovic D
Leuk Lymphoma; 2019 Dec; 60(12):3090-3091. PubMed ID: 31184233
[No Abstract] [Full Text] [Related]
[Next] [New Search]
